GSK is a British multinational pharma company and a global leader in vaccines and respiratory medicines. Following the consumer healthcare spin-off (Haleon, 2022), GSK is focused on pharmaceuticals and vaccines.
Vaccines, Respiratory, HIV, Immunology
5-year financial trajectory
Business segment breakdown
Key product revenue comparison
Geographic revenue split
| Product | Indication | Revenue |
|---|---|---|
| Trelegy (fluticasone/umeclidinium/vilanterol) | Respiratory (COPD/asthma) | $5.0B |
| Shingrix (zoster vaccine) | Vaccines (shingles) | $3.8B |
| Nucala (mepolizumab) | Asthma (eosinophilic) | $2.0B |
| Jemperli (dostarlimab) | Oncology (endometrial) | $0.2B |
| Arexvy (RSV vaccine) | Vaccines (RSV) | $1.2B |
| Dovato (dolutegravir/3TC) | HIV | $2.0B |
GSK is the #10 pharma company. Post-Haleon spin-off, it is a focused pharma/vaccines company. Arexvy (first RSV vaccine) and Shingrix are key vaccine growth drivers. ViiV Healthcare (HIV JV with Pfizer) provides stable revenue.
Revenue projected to grow to $35B+ by 2026. Arexvy (RSV) is a major new vaccine franchise. Trelegy continues to gain share in respiratory. Jemperli (oncology) and depemokimab (long-acting IL-5) represent pipeline growth.
GSK 2023 Annual Report. Revenue and financial data from SEC filings (Form 10-K/20-F). Pipeline data from company R&D presentations and ClinicalTrials.gov. Market analysis by Medifirm Intelledge Global.